These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

763 related items for PubMed ID: 2896559

  • 1. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR, Tankanow RM, Nostrant TT.
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [Abstract] [Full Text] [Related]

  • 2. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [Abstract] [Full Text] [Related]

  • 3. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM, Clissold SP.
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [Abstract] [Full Text] [Related]

  • 4. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
    Langtry HD, Grant SM, Goa KL.
    Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
    [Abstract] [Full Text] [Related]

  • 5. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W.
    J Int Med Res; 1989 Oct; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [Abstract] [Full Text] [Related]

  • 6. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT.
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.
    Thomson AB, Mahachai V.
    Clin Invest Med; 1987 May; 10(3):152-70. PubMed ID: 2887321
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM, Vinayek R, Maton PN, Wank SA, Gardner JD, Jensen RT.
    J Clin Gastroenterol; 1987 May; 9 Suppl 2():23-5. PubMed ID: 2887615
    [Abstract] [Full Text] [Related]

  • 11. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT.
    Am J Med; 1986 Oct 24; 81(4B):49-59. PubMed ID: 2877575
    [Abstract] [Full Text] [Related]

  • 12. Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
    Savarino V, Mela GS, Scalabrini P, Sumberaz A, Fera G, Zentilin P, Celle G.
    Am J Gastroenterol; 1988 Sep 24; 83(9):917-22. PubMed ID: 2901220
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Famotidine in the USA: a review of efficacy studies.
    Gitnick G.
    J Int Med Res; 1989 Sep 24; 17 Suppl 1():17A-24A. PubMed ID: 2566539
    [Abstract] [Full Text] [Related]

  • 16. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
    Bianchi Porro G.
    Digestion; 1985 Sep 24; 32 Suppl 1():62-9. PubMed ID: 2866137
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine.
    Scarpignato C, Tramacere R, Zappia L.
    Br J Pharmacol; 1987 Sep 24; 92(1):153-9. PubMed ID: 2889492
    [Abstract] [Full Text] [Related]

  • 19. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG, Gottlieb WR, Walter TA, Dreyer M, Müller P, Simon B, Keohane P.
    Hepatogastroenterology; 1986 Oct 24; 33(5):217-20. PubMed ID: 2879782
    [Abstract] [Full Text] [Related]

  • 20. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
    Khasawneh SM, Affarah HB.
    Am J Gastroenterol; 1992 Sep 24; 87(9):1180-2. PubMed ID: 1519576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.